Newron Raises €38M to Advance Phase III Schizophrenia Drug Trial

Event summary

  • Newron secures up to €38M in funding from existing and new shareholders to advance its Phase III ENIGMA-TRS program for evenamide, a potential first-in-class treatment for treatment-resistant schizophrenia (TRS).
  • Initial tranche of €15M raised through subscription of up to 779,624 newly issued shares at €19.24 per share, with additional tranches contingent on clinical trial progress and positive results.
  • ENIGMA-TRS 1 and 2 pivotal studies expected to report 12-week results by Q4 2026, with full results anticipated by November 30, 2026.
  • Evenamide targets glutamatergic dysfunction in TRS, a condition affecting 15-50% of schizophrenia patients and currently lacking effective treatment options.

The big picture

Newron's €38M funding round underscores the strategic importance of evenamide in addressing treatment-resistant schizophrenia, a condition with limited therapeutic options. The investment comes as the company advances its Phase III clinical trials, positioning evenamide as a potential first-in-class glutamate modulator. The success of these trials could validate Newron's approach to targeting glutamatergic dysfunction, a key differentiator in the competitive neuroscience space.

What we're watching

Clinical Trial Outcomes
The pace at which ENIGMA-TRS 1 and 2 studies deliver positive results will determine the timing and scale of additional funding tranches.
Market Differentiation
Whether evenamide can establish itself as a first-in-class treatment for TRS, addressing a significant unmet need in the schizophrenia market.
Strategic Partnerships
How Newron's existing partnerships with EA Pharma, Myung In Pharm, and others will influence the global commercialization of evenamide.